Valuation: Novartis AG

Market Cap 273B 243B 227B 207B 389B 26,312B 395B 2,746B 1,063B 13,400B 1,026B 1,004B 43,040B P/E 2026 *
20.4x
P/E 2027 * 17x
Enterprise Value 305B 271B 253B 231B 434B 29,338B 440B 3,062B 1,185B 14,941B 1,144B 1,119B 47,990B EV / Sales 2026 *
5.28x
EV / Sales 2027 * 4.91x
Free-Float
91.66%
Yield 2026 *
3.02%
Yield 2027 * 3.15%
1 week+0.02%
1 month-5.56%
3 months-8.52%
6 months-4.32%
Current year+6.11%
1 week 124.76
Extreme 124.76
129.38
1 month 117.32
Extreme 117.32
141.26
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Compliance Officer 58 14/04/2025
Director TitleAgeSince
Director/Board Member 67 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
+0.81%+3.98%+15.21% - 273B
-0.92%-2.97%+38.93%+113.04% 1,031B
-2.01%-4.01%+39.65%+67.46% 638B
-0.82%-2.08%+6.23%+75.11% 462B
-0.97%-2.55%+60.00%+40.62% 359B
-0.03%-3.96%+23.63%+40.70% 335B
-1.58%-0.76%+13.50%+26.44% 273B
-2.02%-2.97%-3.25%+9.88% 253B
-2.74%+1.11%+37.54%+54.16% 228B
-0.94%-1.39%+32.80%+99.20% 185B
Average -1.35%-0.36%+26.42%+58.51% 418.21B
Weighted average by Cap. -1.26%-0.35%+29.57%+69.86%

Financials

2026 *2027 *
Net sales 57.67B 51.22B 47.9B 43.65B 82.18B 5,552B 83.31B 579B 224B 2,828B 217B 212B 9,083B 61.42B 54.55B 51.02B 46.49B 87.52B 5,913B 88.73B 617B 239B 3,012B 231B 226B 9,673B
Net income 14.21B 12.62B 11.8B 10.76B 20.25B 1,368B 20.53B 143B 55.27B 697B 53.35B 52.19B 2,238B 15.78B 14.02B 13.11B 11.95B 22.49B 1,520B 22.8B 159B 61.39B 774B 59.26B 57.97B 2,486B
Net Debt 31.43B 27.92B 26.11B 23.79B 44.79B 3,026B 45.41B 316B 122B 1,541B 118B 115B 4,950B 28.26B 25.1B 23.48B 21.39B 40.27B 2,721B 40.83B 284B 110B 1,386B 106B 104B 4,451B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Date Price Change
01/10/26 €126.48 +0.81%
30/09/26 €125.46 -2.37%
29/09/26 €128.50 -0.59%
28/09/26 €129.26 +1.57%
25/09/26 €127.26 +0.68%
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
143.78USD
Average target price
151.76USD
Spread / Average Target
+5.55%

Quarterly revenue - Rate of surprise